HomeVoclosporin

Voclosporin

Also known as: Lupkynis

Calcineurin Inhibitor ImmunosuppressantCalcineurin InhibitorsP-Glycoprotein Inhibitors

Route: Oral

Check Voclosporin Interactions →
12 interactions on record⛔ Black Box Warning

Voclosporin has 12 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 6 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Clarithromycin, Itraconazole, Ketoconazole. Patients taking Voclosporin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total
12
Contraindicated
3
Major
6
Moderate
3

Contraindicated (3)

  • Voclosporin + ClarithromycinCo-administration of LUPKYNIS with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is contra
  • Voclosporin + ItraconazoleCo-administration of LUPKYNIS with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is contra
  • Voclosporin + KetoconazoleCo-administration of LUPKYNIS with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) is contra

Major (6)

  • Voclosporin + AtorvastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + FluvastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + PitavastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + PravastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + RosuvastatinOATP1B1/OATP1B3 substrate; voclosporin increases exposure. Monitor for myopathy and rhabdomyolysis; reduce dosage as rec
  • Voclosporin + SimvastatinOATP1B1 substrate; voclosporin increases simvastatin acid exposure 3.1-fold (Cmax) and 1.8-fold (AUC). Monitor for myopa

Moderate (3)

  • Voclosporin + DiltiazemModerate CYP3A4 inhibitor that increases voclosporin exposure; dosage reduction of voclosporin required.
  • Voclosporin + FluconazoleReduce LUPKYNIS dosage when co-administered with moderate CYP3A4 inhibitors (e.g., verapamil, fluconazole, diltiazem) [s
  • Voclosporin + VerapamilModerate CYP3A4 inhibitor that increases voclosporin exposure; dosage reduction of voclosporin required.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.